Biotechnology company developing therapeutic candidates targeting drug-resistant and devastating cancers using ferroptosis

    Randy Milby, the Chief Executive Officer and Chairman of <a href="https://hillstreambio.com" target="_blank" rel="noreferrer noopener">Hillstream BioPharma</a>, a biotechnology company developing therapeutic candidates targeting drug-resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death, and immuno-oncology targeted novel biologics joins eHealth Radio and the <a href="https://ehealthradio.podbean.com/category/cancer-information" target="_blank" rel="noreferrer noopener">Cancer Information</a> &amp; <a href="https://ehealthradio.podbean.com/category/health-news" target="_blank" rel="noreferrer noopener">Health News</a> Channels. Listen to interview with host <a href="https://www.linkedin.com/in/ericmdye/" target="_blank" rel="noreferrer noopener">Eric Michaels</a> and guest Randy Milby discuss the following: <ol><li>Please tell us a bit about your background and Hillstream BioPharma.</li><li>What developments are currently in Hillstream’s pipeline?</li><li>How does ferroptosis-targeted therapy differentiate from other cancer treatments currently available or under development?</li><li>Why is it important to Hillstream to develop drug resistant therapeutics for cancers with few treatment options?</li><li>What advice can you share with industry peers, key opinion leaders, or anyone pursuing R&amp;D in the biotechnology space?</li><li>Looking ahead, what exciting advances do you think are on the horizon for Hillstream?</li></ol>Mr. Milby previously served as Chief Executive Officer and Member of the Board of Directors at CorMedix, a publicly traded biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of inflammatory and infectious diseases. He is a seasoned executive who led the increase in market capitalization from $3M to a peak of $350M of Cormedix while improving the company’s financial position with capital raises from equity markets. He oversaw efforts to gain CE